Search clinical trials for: BMS-986205

Total 1978 results

Bristol-Myers Squibb

Available

Expanded Access for Repotrectinib
Bristol-Myers Squibb

Terminated

A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

Heart Failure

Spain, United Kingdom, Netherlands, Czechia, Poland
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults

Obese But Otherwise Healthy Participants

United States
Bristol-Myers Squibb

Terminated

A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Rheumatoid Arthritis | Inflammatory Bowel Diseases | Psoriasis | Nonalcoholic Steatohepatitis | Ankylosing Spondylitis

Netherlands
Cedars-Sinai Medical Center
Bristol-Myers Squibb

Terminated

A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer

Urogenital Neoplasms | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Male | Prostatic Neoplasms | Prostatic Diseases | Genital Diseases, Male

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects

Severe Sepsis

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body

Liver Fibrosis/NASH

United States
Bristol-Myers Squibb

Withdrawn

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Scleroderma

United Kingdom, United States, Poland, Canada
Bristol-Myers Squibb

Completed

Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, Australia, United States
Bristol-Myers Squibb

Not yet recruiting

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Canada
Celgene

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

Healthy Male Participants

United States
Allyx Therapeutics
Michael J. Fox Foundation for Parkinson's Research

Active, not recruiting

Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers

Dementia | Alzheimer Disease

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

Healthy Participants

United States
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

Hungary, Czechia
Bristol-Myers Squibb

Completed

Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants

Thrombosis

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants

Heart Decompensation, Acute

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects

Arthritis

United States
Bristol-Myers Squibb

Terminated

A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy

Breast Cancer

United States
Bristol-Myers Squibb

Completed

Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors

Cancer

Japan
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants

Healthy

China
Bristol-Myers Squibb
Exelixis

Completed

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Basal Cell Carcinoma (BCC) | Hedgehog Pathway | Smoothened | Basal Cell Nevoid Syndrome (BCNS)

United States, Canada
Bristol-Myers Squibb

Withdrawn

Japanese Phase 1 Study of BMS-844203 (CT322)

Neoplasms

Japan
Lu Jiang

Completed

Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.)

Caffeine | Burning Mouth Syndrome

China
University Children's Hospital, Zurich

Active, not recruiting

Brain Maturation and Sleep (BMS)

Healthy

Switzerland
National Cancer Institute (NCI)

Active, not recruiting

BMS-986253 in Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Celgene

Recruiting

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Terminated

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment

Hepatic Insufficiency

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

BMS-214662 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants

Healthy Volunteers

China
Bristol-Myers Squibb

Completed

Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

Acute Decompensated Heart Failure

United Kingdom, Israel, Argentina, Czechia, Greece, Poland
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986235 in Healthy Subjects

Mediators of Inflammation

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

Liver Fibrosis | Hepatic Cirrhosis

United States
Bristol-Myers Squibb

Completed

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986278 Given to Healthy Participants

Healthy Participants

United Kingdom, Netherlands
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc

Completed

A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Heart Failure
Bristol-Myers Squibb

Withdrawn

Japanese Bridging Study Conducted in the United States

Hepatitis C Virus

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-816336 in Healthy Male Subjects

Dyslipidemia | Diabetes Mellitus, Non-Insulin-Dependent

Australia
Bristol-Myers Squibb

Completed

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

Alzheimer's Disease

United States
Bristol-Myers Squibb

Completed

A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Solid Tumors

Japan
Bristol-Myers Squibb

Completed

A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors

Cancer | Tumor

United States, Spain, Canada, France
Bristol-Myers Squibb

Completed

Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese (JMAD)

Healthy

Japan
Bristol-Myers Squibb

Completed

A Study of BMS-562086 in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Bristol-Myers Squibb

Terminated

Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

Non-small Cell Lung Cancer

Spain, Belgium, France, Italy, Netherlands, Canada, United Kingdom, United States

3

Subscribe